Blog
Omyanutra® 300 from Omya
Posted by Chemlink in Pharmaceutical Products | 0 comments
Omyanutra® 300 is a range of highly compactable porous mineral excipients that have been specifically developed for nutraceuticals. Omya is a global leader in the production of industrial minerals, and these new generation excipients help to overcome and facilitate the various challenges that formulators face when developing nutraceutical tablets. This unique range has a mechanical binding and higher mechanical stability and gives formulators the ability to form hard tablets at a low compression force.
Making Pharmaceuticals UK 2023
Posted by Chemlink in Chemlink Updates, Pharmaceutical Products | 0 comments
In April, Chemlink Specialties joined Harke Pharma at Making Pharmaceuticals UK 2023, the leading UK pharmaceutical exhibition & conference. This year the event was held in Coventry and provided an excellent platform to bring together a wide range of exhibitors and delegates from across the pharmaceutical industry to discuss, showcase and learn about all things pharma.
Introducing Our New Pharma Principal: Omya
Posted by Chemlink in Chemlink Updates, Pharmaceutical Products | 0 comments
We’re pleased to welcome Omya to HARKE GROUP’s Life Sciences Division as one of our exciting new principals. Chemlink Specialities will offer the range of natural and functionalized Calcium Carbonates in the UK and Ireland. In this blog post, we’ll introduce you to the company and its current pharmaceutical and nutraceutical range and explain how you can request samples!
SmartEx® Plus: a New Co-Processed Excipient for Oral Disintegration Tablets
Posted by Chemlink in Pharmaceutical Products | 0 comments
SmartEx® Plus is an exciting new co-processed excipient that has been developed by Japanese chemical company Shin-Etsu to meet the increased demand for oral disintegration tablets (ODTs), with the added advantage that it offers excellent stability without compromising on disintegration time.
Reducing nitrosamines in pharmaceutical formulations
Posted by Chemlink in Pharmaceutical Products, Regulations | 0 comments
There is growing concern over nitrosamines’ existence in pharmaceutical formulations. In this blog we explain the current issues with nitrosamines in pharmaceutical formulations, provide two possible solutions, and we also have a webinar on the topic coming up which you can request an invite for.
Plastic Packaging Tax
Posted by Chemlink in Automotive Care Products, Chemlink Lab, Household Care Products, Industrial Products, Personal Care Products, Pharmaceutical Products, Regulations | 0 comments
A £200 per tonne plastic tax will come into effect from the 1st April 2022 in the UK, what does it mean for our industry and how can we minimise the impact of this tax?
Motusflex®: A New Carbomer Alternative from Clariant
Posted by Chemlink in Chemlink Lab, Chemlink Updates, Pharmaceutical Products | 0 comments
Carbomers impart a silky feel to topical pharmaceutical formulations, but they do require neutralisation to do so. Chemlink are pleased to introduce a high-efficacy alternative to carbomers which require no neutrilisation, simply add to water!
Alternatives To Titanium Dioxide
Posted by Chemlink in Pharmaceutical Products, Regulations | 0 comments
Last month the European Food Safety Authority (EFSA) announced that titanium dioxide is no longer considered ‘safe’ for use as a food additive.
Pharm-a-spheres
Posted by Chemlink in Pharmaceutical Products | 0 comments
Used extensively as an excipient for sustained-release pellets, sugar spheres and their characteristics open a world of possibilities.
Oral-Dispersible-Tablet Formulation Challenges
Posted by Chemlink in Chemlink Lab, Pharmaceutical Products | 0 comments
On Weds 27th May, Shilpa Mistry, our head of Pharma for UK and Ireland, delivered a webinar for Making Pharma on the challenges of formulating oral-dispersible-tablets (ODTs). In this blog we provide an overview of her presentation and the featured products for anyone who missed out on the webinar or who is looking for further details.
